BioSpace News Archive

PUR Biologics, a subsidiary of HippoFi, Inc. (OTC PINK:ORHB), is proud to announce the launch of PURcoreTM, a unique moldable synthetic with an interconnected micro-pore structure for spine surgery.

City of Hope today announced the appointment of John D. Carpten, Ph.D., as director of the National Cancer Institute-designated comprehensive cancer center, director of Beckman Research Institute of City of Hope and chief scientific officer.

Torrent Pharma has begun shipping the generic version of Xeris’s Keveyis® (dichlorphenamide), 50mg tablets, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.

Prapela, Inc., an infant health company in Biddeford, ME, was awarded a grant through the National Institutes of Health (NIH) Blueprint MedTech program and National Institute on Drug Abuse (NIDA), to support the development and evaluation of Prapela’s pad to treat apnea in preterm newborns in collaboration with neonatologists at Tufts Medical Center and the University of Alabama at Birmingham.

Alpha Cancer Technologies Inc. (ACT) today announced the publication of pre-clinical study results in Cancer Cell International highlighting the company’s recombinant human AFP (ACT-101) conjugate with maytansine in mouse xenograft models of colorectal cancer.

DM Clinical Research was named the 2023 Best Clinical Trial Network at the annual Vaccine Industry Excellence (ViE) Awards held during the World Vaccine Congress Washington, the leading global vaccine congress.

Mekonos announced today that Dr. Anil Narasimha, CEO & Co-Founder, will present at the annual Cell & Gene Meeting on the Med to be held April 12-14 in Barcelona, Spain and livestreamed globally.

Mersana Therapeutics, Inc. announced that on April 3, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 77,550 shares of its common stock and restricted stock unit awards to acquire an aggregate of 132,925 shares of its common stock, to 10 new employees whose employment commenced in March 2023.

ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2023 on Thursday, April 27, 2023, after the New York Stock Exchange closes.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.